Category Archives: Side Effects

Long term phase 1 data for Ceritinib

On March 10 an article was published on the long term results of a phase 1 trial of Ceritinib. The trial enrolled 255 patients from January 2011 and July 2013 of whom 246 had ALK + lung cancer. Data cutoff … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment, Side Effects | Leave a comment

Phase 2 Alectinib preliminary results

Article published February 17, 2016. Phase 2 study of Alectinib is ongoing and patients are still being treated.  Patients enrolled from September 2013 to August 2014. All 69 patients had been pretreated with Crizotinib. Study done in USA and Canada. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Alectinib approved by FDA

The FDA conditionally approved alectinib (brand name Alecensa) on December 11, 2015 as a second line treatment. This approval came less than 3 months after the FDA application was filed. The approval was based on results from two single-arm clinical trials. … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research, Side Effects | Leave a comment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Ignyta announced results of phase 1 trial and start of phase 2 trial

As of September 30, 2015. Two Phase 1 results: Total of 92 patients 18 patients met phase 2 eligibility requirements and took phase 2 dose level Among 18 patients 72% respose rate. 4 of 6 (66%) ALK+ patients responded. Drug … Continue reading

Posted in Lung cancer, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects | Leave a comment

ASCO links

Here are 18 ALK+ related abstract links related to the drugs listed below. On the ASCO website 77 abstracts refered to both “ALK” and “Inhibitor”.  When I get a chance I will write up a summary on some of the … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro | Leave a comment

Update on Alectinib trial in Japan

Here is a research article that describes the results of the Alectinib trial in Japan of Crizotinib naive patients two years after the last patient enrolled. In the phase 2 portion, 93.5 % of patients achieved an objective response.  Partial … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Research, Side Effects | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

5-6 minute video by OncLive

The discussion is about Ceritinib by Novartis and AP26113 by Ariad. The main speakers are Dr. Shaw and Dr. Cambidge. https://m.youtube.com/watch?v=vRHm7XTE3fw Seems like it was recorded in May or June 2014.

Posted in AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Resistance to treatment, Side Effects | Leave a comment

Ariad AP26113 update

137 patients total, focus on phase 2 cohort of first trial of 79 patients. Early onset pulmonary symptoms reduced to 4% in phase 2. 72% objective response in phase 2. “Tumor shrinkage in nearly all patients.” 16 patients had 100% … Continue reading

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Resistance to treatment, Side Effects | Leave a comment